Eli Lilly’s Obesity Drug Combo Shows Strong Weight Loss in Early Trial

Phase 2b trial with 367 adults with obesity and type 2 diabetes found a combination of Mounjaro and an experimental drug produced 23.3% average weight loss after 48 weeks—significantly more than monot

Eli Lilly’s 48-week Phase 2b trial with 367 adults diagnosed with obesity and type 2 diabetes revealed that a combination of eloralintide and tirzepatide (Mounjaro) at 9 mg and 15 mg doses produced an average weight loss of 23.3% after 48 weeks—compared to 14.8% for tirzepatide alone. The therapy also improved blood glucose control, reducing HbA1c by 2.9% versus 2.4% for monotherapy. Discontinuation rates were higher in the combo group: up to 25% of participants stopped treatment due to adverse events, versus 3% for tirzepatide alone. The study, reported via pharmaceutical press release but not peer-reviewed, requires confirmation in larger trials due to its small sample size and focus on type 2 diabetes patients.

This combination therapy’s potential lies in its ability to address obesity and diabetes simultaneously—a dual burden that affects millions globally. If Phase 3 trials validate these results, it could lower the cost of effective obesity treatment by reducing reliance on multiple medications and hospitalizations. For now, the therapy remains experimental and restricted to adults with both conditions.

What matters next: Eli Lilly’s planned Phase 3 testing with optimized dosing and a single-injection formulation. The findings require larger trials to confirm safety and efficacy beyond this specific patient group. The current results are promising but limited to type 2 diabetes patients and not yet peer-reviewed.

Source: New Atlas